1. The overt form of carnitine palmitoyltransferase (CPT,) in rat liver and heart mitochondria was inhibited by DL-2-bromopalmitoyl-CoA and bromoacetyl-CoA. SMethanesulphonyl-CoA inhibited liver CPT1. 2. The inhibitory potency of DL-2-bromopalmitoyl-CoA was 17 times greater with liver than with heart CPT,. Inhibition of CPT, by DL-2-bromopalmitoyl-CoA was unaffected by 5,5'-dithiobis-(2-nitrobenzoic acid) or (in liver) by starvation. 3. In experiments in which DL-2-bromopalmitoyl-CoA displaced [14C]malonyl-CoA bound to liver mitochondria, the KD (competing) was 25 times the IC50 for inhibition of CPT, providing evidence that the malonyl-CoA-binding site is unlikely to be the same as the acyl-CoA substrate site. 4. Bromoacetyl-CoA inhibition of CPT, was more potent in heart than in liver mitochondria and was diminished by 5,5'-dithiobis-(2-nitrobenzoic acid) or (in liver) by starvation. Bromoacetyl-CoA displaced bound ['4C]malonyl-CoA from heart and liver mitochondria. In heart mitochondria this displacement was competitive with malonyl-CoA and was considerably facilitated by L-carnitine. In liver mitochondria this synergism between carnitine and bromoacetyl-CoA was not observed. It is suggested that bromoacetyl-CoA interacts with the malonyl-CoA-binding site of CPT,. 5. L-Carnitine also facilitated the displacement by DL-2-bromopalmitoyl-CoA of [14C]malonyl-CoA from heart, but not from liver, mitochondria. 6. DL-2-Bromopalmitoyl-CoA and bromoacetyl-CoA also inhibited overt carnitine octanoyltransferase in liver and heart mitochondria. 7. These findings are discussed in relation to inter-tissue differences in (a) the response of CPT, activity to various inhibitors and (b) the relationship between high-affinity malonyl-CoA-binding sites and those sites for binding of L-carnitine and acyl-CoA substrates.
from the heart enzyme. Differences include: the effects of [K+] and [Mg2+] (Saggerson, 1982) , sensitivity to malonyl-CoA (Saggerson & Carpenter, 1981b; Mills et al., 1983 Mills et al., , 1984 Cook, 1984) , KD values for high-affinity binding of malonyl-CoA to mitochondria (Bird & Saggerson, 1984) , the apparent Km for carnitine Mills et al., 1984) and long-term adaptive changes in both specific activity and sensitivity to malonyl-CoA, which are seen in liver but not in heart (Saggerson & Carpenter, 198 la; Veerkamp & Van Moerkerk, 1982) . It is not known at present whether these differences reflect the presence of tissue-specific CPT, isoenzymes.
Mitochondria from mammalian tissues also contain an overt medium-chain carnitine acyltransferase activity (Markwell et al., 1977; Choi et al., 1977; Saggerson & Carpenter, 1981b) . The acyl-chain-length specificity of this proposed enzyme is likely to overlap with those of carnitine acetyltransferase and CPT. Clarke & Bieber (1981) have proposed that heart COT is attributable to these latter activities, and is unlikely to be a distinct enzyme. It is still unresolved whether liver mitochondria contain a distinct overt COT enzyme, although it has been demonstrated that liver overt COT and CPT1 activities differ in several respects, e.g. response to [K+] and [Mg2+] , the effect of Nbs,, sensitivity to malonyl-CoA and kinetics with respect to [acyl-CoA] (Saggerson & Carpenter, 1981a ,c, 1982b Saggerson, 1982) .
In the present study we have investigated the effects of bromoacetyl-CoA and 2-bromopalmitoyl-CoA on CPT, and overt COT activities and on [14C]malonyl-CoA binding in heart and liver mitochondria. The findings provide further information both about inter-tissue differences in CPT, activities and about the relationship between the malonyl-CoA-binding site and the catalytic site of CPT, .
Materials and methods Animals and chemicals
Sources of these were as described by Saggerson (1982) and Bird & Saggerson (1984) . In addition, bromoacetyl chloride, methanesulphonyl chloride, 2-bromopalmitic acid, oxalyl chloride and NNdimethylformamide were from Aldrich Chemical Co., Gillingham, Dorset,-U.K.
Chemical synthesis 2-Bromopalmitoyl-CoA, bromoacetyl-CoA and methanesulphonyl-CoA were prepared from acid chlorides and CoA (Seubert, 1960) . 2-Bromopalmitoyl-CoA was synthesized from 2-bromopalmitic acid via 2-bromopalmitoyl chloride as described by Chase & Tubbs (1972) . For methanesulphonylCoA, the method of Owens et al. (1981) was modified in that 10mg of CoA were made to react at 0°C with 101 of methanesulphonyl chloride in 1 M-KHCO3, pH 8.0, with vigorous shaking for 30s. The product, after diethyl ether extractions, was not further purified. Bromoacetyl-CoA was prepared by a similar method, but with 10mg of CoA and lOjl of bromoacetyl chloride. All three acyl-CoAs were stored at -20°C as aqueous solutions, pH3-5. Concentrations were determined from u. v. spectra, assuming £260 = 14.6 x 103. In addition, 2-bromopalmitoylCoA was assayed enzymically by measuring the release of CoA catalysed by a partially purified rat brain palmitoyl-CoA hydrolase (EC 3.1.2.2) (Anderson & Erwin, 1971 ) in a Nbs,-linked assay (Knauer, 1979) . This method gave similar values to those obtained from A,60 measurements. The contamination with free thiol was determined by reaction with Nbs, at pH8, and was less than 1% for methanesulphonyl-CoA and 2-bromopalmitoyl-CoA, and approx. 5% for bromoacetylCoA.
Isolation of mitochondria
Rat liver and heart mitochondria were obtained as described by Saggerson (1982) and finally suspended in 0.3M-sucrose medium containing lOmM-Tris/HCl buffer (pH 7.4) and 1 mM-EGTA. Enzyme assays CPT, and overt COT activities were assayed at 25°C in intact freshly prepared mitochondria by a radiochemical method (Saggerson, 1982) . The assays contained 25mM-Tris/HCl buffer (pH7.4), 150mM-sucrose, 60mM-KCl, fatty acid-poor albumin (1.3mg/ml), 1 mM-EGTA and (unless otherwise stated) 40/iM-palmitoyl-CoA or 40uM-octanoyl-CoA. Mitochondria were preincubated in this medium for 2min before addition of 400pM-Lcarnitine and DL-[methyl-3H]carnitine (1,Ci/ml), giving a final volume of 1 ml. After 4min the reaction was terminated, and incorporation of 3H into butan-1 -ol-soluble products determined as described by Saggerson et al. (1982) . Bird & Saggerson (1984) . Liver mitochondria or heart mitochondria were incubated with [2-'4C]malonylCoA at 0-4°C for 20min in 1.0ml containing 25mM-Tris/HCl buffer (pH7.4), 150mM-sucrose, 60mM-KCl, fatty acid-poor albumin (1.3mg/ml), 1 mM-EGTA and other additions as indicated. Again, dithiothreitol was omitted from these assays, and additions of 2-bromopalmitoyl-CoA or bromoacetyl-CoA were made immediately before addition of mitochondria. Non-specific entrapment of [I 4C]malonyl-CoA was taken as the radioactivity remaining bound in the presence of 0.5mm unlabelled malonyl-CoA and was subtracted from all values to give the amount of specifically bound malonyl-CoA.
Analysis of results
The maximum inhibitions (Imax) of CPT1 and overt COT activities were determined from graphs of (%O inhibition)-' versus [inhibitor]-' by extrapolation to infinite [inhibitor] (Saggerson & Carpenter, 1981a) . Values for IC50 were also determined from these graphs, by using linear regression, where they were linear. In other cases IC50 values were read from the graphs of % inhibition versus [inhibitor]-' after subtraction of non-inhibitable activity. Statistical significance was determined by using Student's t test for unpaired samples.
Results and discussion
Inhibition of CPT, by DL-2-bromopalmitoyl-CoA, bromoacetyl-CoA and S-methanesulphonyl-CoA CPT activity was measured in the direction of palmitoylcarnitine formation in an iso-osmotic medium, by using intact mitochondria. Under these conditions the measured CPT activity corresponded to the overt pool, or CPT,. This was verified by observing the effect of malonyl-CoA, which commonly gave approx. 90% of maximal inhibition in both heart and liver mitochondria, with IC50 values similar to those previously reported under similar assay conditions (Saggerson & Carpenter, 198 la, b) . DL-2-Bromopalmitoyl-CoA is an established inhibitor of palmitoyl-CoA oxidation by rat liver mitochondria (Chase & Tubbs, 1972) and of soluble CPT, from rat liver (Hoppel & Tomec, 1972) and ox liver (West et al., 1971) . It is presumed that this inhibition is at the catalytic site, and it is thought (West et al., 1971; Chase & Tubbs, 1972) that the mechanism of inhibition is similar to the carnitine-dependent inhibition of carnitine acetyltransferase by bromoacetyl-CoA (Chase & Tubbs, 1969) . Potent inhibition of CPT, in liver mitochondria by 2-bromopalmitoyl-CoA (Fig. la) was therefore expected. Previous work has indicated that this inhibition would not be readily reversible on dilution (West et al., 1971) . We have confirmed this in an experiment in which liver mitochondria from a fed rat were preincubated at 0-4°C with 400 juM-carnitine and 0, 2 iM-or 10 luM-DL-2-bromopalmitoyl-CoA. After 2 min these incubations were diluted 20-fold and CPT, assays performed with 40uM-palmitoyl-CoA. The resulting inhibitions were 45% and 88% after preincubation with 2jiM-and 10M-2-bromopalmitoyl-CoA respectively. These values may be contrasted with 19% and 54% inhibition obtained when the liver enzyme was assayed directly with 0.1 gm and 0.5 pM-2-bromopalmitoyl-CoA respectively without preincubation. The IC50 value for the liver enzyme was unaltered on starvation (Table 1) and was similar to that for inhibition of palmitoyl-CoA oxidation by rat liver mitochondria (Tubbs et al., 1980) . The absolute numerical values should, however, be treated with some caution, since the inhibitor presumably is largely bound to the albumin in the assay. It was most surprising to find that CPT1 in intact heart mitochondria was inhibited far less potently by 2-bromopalmitoylCoA ( Fig. la) , with an IC50 value approx. 17 times higher than for liver (Table 1) . This difference could not be accounted for by changes in assay conditions, since the CPT, activities and mitochondrial protein concentrations in the assays were similar for heart mitochondria and for those from liver of starved rats. Although other explanations are possible, this finding is consistent with heart and liver containing different CPT1 isoenzymes. 2-Bromopalmitate inhibits palmitate oxidation in intact heart and in hepatocytes (Burgess et al., 1968; Sauer et al., 1971 ), but there is insufficient information to indicate whether there are inter-tissue differences in the effects of the inhibitor at this level.
Bromoacetyl-CoA, in the presence of L-carnitine, is an active-site-directed inhibitor of carnitine acetyltransferase (Chase & Tubbs, 1969) . Bromoacetyl-CoA has not previously been investigated as an inhibitor of CPT, except by Miyazawa et al. (1983) , who reported that, like malonyl-CoA, it was ineffective against solubilized purified rat liver CPT. Since CPT, in mitochondria from rat heart or liver can, in addition to malonyl-CoA, be inhibited by other short-chain acyl-CoA esters (succinyl-CoA, methylmalonyl-CoA, propionylCoA), it was decided to test the effect of bromoacetyl-CoA against the enzyme in situ in intact mitochondria. It was also considered possVol. 230 CPT, assays were performed as described in the Materials and methods section. L-Carnitine and palmitoyl-CoA were present at 400pM and 40pM respectively. CPT, activities with these substrates alone were 4.83+0.45, 9.47 + 0.53 and 9.80 + 1 .44nmol/min per mg of protein for mitochondria from fed rat liver, 24h-starved-rat liver and heart respectively. Nbs, (150pM) increased this rate by 7% in liver mitochondria and decreased this rate by 40% in heart mitochondria. All values are expressed as percentages of these activities in the absence of inhibitory acylCoAs. In (a) and ( Table 3 ) in experiments where mitochondria were preincubated with the inhibitor before assay. As shown in Fig. 1(b) , bromoacetyl-CoA was a very effective inhibitor of both heart and liver CPT, with IC50 values in the range 0.1-1 HIM (Table 1) , these being one to two orders of magnitude lower than the values for inhibition by acetyl-CoA . Unlike DL-2-bromopalmitoyl-CoA, but like malonyl-CoA (Saggerson & Carpenter, 1981a,b) , the IC50 of bromoacetyl-CoA for CPT, was significantly increased in liver on starvation and was lower in heart than in liver. The effect of bromoacetyl-CoA showed several other similarities to the effect of malonyl-CoA. First, the effect of bromoacetyl-CoA was abolished when CPT was solubilized with Triton X-100 (results not shown).
The effect of malonyl-CoA is also lost when heart or liver CPT is solubilized (McGarry et al., 1978; Saggerson, 1982) . Second, as seen with malonylCoA (Saggerson & Carpenter, 1982b) , the sensitivity of liver or heart CPT, to bromoacetyl-CoA was considerably decreased by Nbs2 ( Palmitoyl-CoA (gM) (Fig. 2) . Malonyl-CoA has a similar effect on CPT, idi liver (Saggerson & Carpenter, 1981c; Cook, 1984) and heart (Saggerson, 1982) tors]-I were linear for both liver and heart CPT1, as predicted for two inhibitors competing for the same inhibitory site (Yonetani, 1982 (Owens et al., 1981) . It has been suggested that, because of the high specificity of the thiolsulphonate group for thiols, S-methanesulphonyl-CoA could be used to detect the presence of a reactive thiol in an acylCoA-binding site (Owens et al., 1981) . S-Methanesulphonyl-CoA was found to inhibit liver CPT, (Fig. Id) and comparable with the inhibition of succinic thiokinase by S-methanesulphonyl-CoA (Owens et al., 1981) . In addition, lOOpM-Nbs2 abolished the inhibitory effect of 50pM-S-methanesulphonyl-CoA (results not shown). Although S-methanesulphonyl-CoA appeared to act in a similar manner to malonylCoA or bromoacetyl-CoA, the 'ma. values were less and the IC50 values much higher with this compound than with bromoacetyl-CoA, and no evidence could be obtained for irreversible timedependent inhibition; therefore investigations with S-methanesulphonyl-CoA were not pursued further.
Inhibition of overt COT by DL-2-bromopalmitoylCoA and bromoacetyl-CoA
The inhibition of overt COT activity in liver and heart mitochondria by 2-bromopalmitoyl-CoA (Fig. 4a) was very similar to the pattern observed for CPT, (Fig. la) . The IC50 values (Table 2) were not significantly different from the corresponding values for CPT1 (Table 1) , and there was no significant change in the sensitivity to this inhibitor of liver COT on starvation. Again, as with CPT,, the heart enzyme showed a surprising insensitivity to the effect of 2-bromopalmitoylCoA. The similar IC50 values for overt COT and CPT, may be coincidental, since octanoyl-CoA probably binds much less tightly than palmitoylCoA to the albumin in the assays. The maximum inhibitable overt COT activities, with 2-bromopalmitoyl-CoA, were always relatively less (by approx. 10%) than for CPT, in parallel experiments with the same mitochondrial preparations.
Malonyl-CoA inhibits overt COT activity in rat Bromoacetyl-CoA (UM) Fig. 4 liver and heart mitochondria. Liver COT is more sensitive to malonyl-CoA than is liver CPT,, and the sensitivity of COT is not affected by starvation (Saggerson & Carpenter, 198 la). Heart overt COT is inhibited by malonyl-CoA concentrations similar to those that inhibit heart CPT,, but only approx. 50% of this COT activity is inhibitable (Saggerson & Carpenter, 1981b shown in Fig. 4(b) and Table 2 is similar to these previously reported effects of malonyl-CoA. The IC50 with bromoacetyl-CoA was significantly lower for COT than for CPT, in liver from both fed (P <0.05) and starved rats (P <0.02), but not significantly different in heart (0.05 < P < 0.1). The maximum inhibitable overt COT activity in heart was only approximately half of the total. Since bromoacetyl-CoA is a potent active-site-directed inhibitor of carnitine acetyltransferase (Chase & Tubbs, 1969) , this non-inhibitable COT activity cannot be attributed to carnitine acetyltransferase.
Likewise, since approx 90% of the heart CPT, is inhibitable by bromoacetyl-CoA (Fig. lb) (presumably through an interaction with the malonyl-CoA site), it seems unlikely that this uninhibitable COT could be CPT. It is therefore concluded that the heart preparation contains a third overt acyltransferase activity distinct from CPT, and carnitine acetyltransferase. This conclusion is at variance with the findings of Clarke & Bieber (1981) . Displacement ofJ[2-' 4C]malonyl-CoAJrom mitochondrial binding sites by 2-bromopalmitoyl-CoA and bromoacetyl-CoA Intuitively, it would seem most likely that 2-bromopalmitoyl-CoA is an inhibitor of CPT, by virtue of an interaction with the acyl-CoA-binding site of the enzyme. If this is so, then the major differences observed in the mode of inhibition by malonyl-CoA compared with 2-bromopalmitoylCoA should support the hypothesis that malonylCoA acts at a separate site. These major differences are as follows. First, 2-bromopalmitoyl-CoA potently inhibits the solubilized liver enzyme (West et al., 1971; Hoppel & Tomec, 1972) , whereas solubilization of the liver enzyme desensitises it to malonyl-CoA (McGarry et al., 1978) . Second, the inhibitory potency of 2-bromopalmitoyl-CoA is unaffected by Nbs. (Table 1) , whereas this thiol-group reagent considerably desensitizes CPT, to malonyl-CoA (Saggerson & Carpenter, 1982b) . Third, starvation does not decrease the sensitivity of liver CPT, to 2-bromopalmitoyl-CoA ( Fig. la; Table 1 ), whereas sensitivity to malonylCoA (Saggerson & Carpenter, 1981a) and bromoacetyl-CoA ( Fig. lb; Table 1 ) is decreased. Fourth, when heart and liver CPT, activities are compared, the relative potency for inhibition by 2-bromopalmitoyl-CoA is the reverse of that for inhibition by malonyl-CoA (Saggerson & Carpenter, 1981 b) or bromoacetyl-CoA (Table 1) .
Palmitoyl-CoA displaces ['4C]malonyl-CoA from binding sites on skeletal muscle, heart and liver mitochondria (Mills et al., , 1984 Bird & Saggerson, 1984 (Bird & Saggerson, 1984) . L-Carnitine alone caused some displacement of ['4C]malonyl-CoA from liver mitochondria, a phenomenon which is described more fully in the accompanying paper . under conditions identical with those used here is 0.1 m (Bird & Saggerson, 1984 (Fig. 6 ), but not entirely in the manner expected. Bromoacetyl-CoA displaced
[14C]malonyl-CoA from liver mitochondria in the presence and absence of carnitine. Carnitine had little effect on the percentage displacement curves in liver, although, by itself, carnitine caused some decrease in malonyl-CoA binding . In view of its greater inhibitory potency against heart compared with liver CPT, (Table 1) , it was therefore surprising to find that bromoacetyl-CoA by itself was rather ineffective at displacing 50nM-[14C]malonyl-CoA from heart mitochondria (Fig. 6) , where 50% displacement was only achieved with lOpM-bromoacetyl-CoA. The KD for malonyl-CoA binding to heart mitochondria high-affinity sites under conditions identical with those used here is 11 nM (Bird & Saggerson, 1984) which, when fitted to eqn. (1), would yield a KD value for bromoacetyl-CoA at this site of 1.8XUM. This is an order of magnitude higher than the IC50 for inhibition of heart CPT1 by bromoacetyl-CoA (Table 1) , and clearly is anomalous. However, inclusion in the binding assay of carnitine (which alone has no effect on malonyl-CoA binding in heart, unlike liver; (Fig. 7) , the KD for bromoacetyl-CoA at the heart malonyl-CoA site in the presence of carnitine was found to be 78 nm, which is not inconsistent with the IC50 for inhibition of heart CPT, of 140nM (Table 1 ). Fig. 7 shows a Scatchard analysis of [14C]malonyl-CoA binding to heart mitochondria over a concentration range which essentially only encompasses interaction with high-affinity sites (Bird & Saggerson, 1984) . The KD for this binding, which was performed in the presence of 400pM-carnitine, was not different from that observed in the absence of carnitine by Bird & Saggerson (1984) . Fig. 7 also shows that bromoacetyl-CoA (in the presence of carnitine) appeared to interact with this binding site in a competitive manner with malonyl-CoA. It was concluded from this series of experiments that carnitine considerably facilitated competition by bromoacetyl-CoA at the high-affinity malonylCoA-binding site in heart mitochondria. It is also noteworthy that Fig. 6 demonstrates a further inter-tissue difference between liver and heart, in that carnitine does not appear to facilitate such an effect of bromoacetyl-CoA in liver mitochondria. In view of the finding that bromoacetyl-CoA causes an extremely persisent active-site-directed inhibition of carnitine acetyltransferase when carnitine is present (Chase & Tubbs, 1969) , the experiment summarized in Table 3 (Mills et al., , 1984 . Finally, the displacement of [14C]malonyl-CoA by 2-bromopalmitoyl-CoA was also investigated with heart mitochondria (Fig. 8) . Again, although carnitine alone had no effect on malonyl-CoA binding (also see , 400pM-carnitine potentiated the displacement by 2-bromopalmitoyl-CoA by approx. 3-fold. This may be contrasted with Fig. 5 , in which no potentiating Vol. 230 Table 3 . Rerersibilinv of effcts of bromoacetyl-CoA in heart mitochondria Heart mitochondria from fed animals (2.9mg of protein/ml) were preincubated for 10min at 0-4°C in 1.5ml of 25mM-Tris/HCI buffer (pH7.4) containing 150mM-sucrose, 60mM-KCI, fatty acid-poor albumin (I.3 mg/ml), I mM-EGTA and: (a) no further additions; (b) 5 uM-bromoacetyl-CoA; or (c) 5 gM-bromoacetylCoA +400,UM-L-carnitine. The mitochondria were then sedimented by centrifugation for 2min at 6500 gay.
in an Eppendorf 5412 centrifuge (at 4°C) and the supernatant was discarded. The pellet was resuspended in 1 .5 ml of ice-cold 0.3 M-sucrose medium containing l OmM-Tris/HCI buffer (pH 7.4) and 1 mM-EGTA and recentrifuged. This washing procedure was repeated, and the mitochondria were finally resuspended in 1.5 ml of the 0.3M-sucrose medium. Portions (50dul and 300,Iu respectively) were taken for CPT, assay and measurement of ['4C]malonyl-CoA binding as described in the Materials and methods section.
[ effect of carnitine was observed in liver mitochondria.
Conclusions
The principal conclusions are as follows. First, the studies with 2-bromopalmitoyl-CoA using liver mitochondria provide further evidence that the malonyl-CoA site is probably distinct from the acyl-CoA substrate-binding site of CPT,. Second, it is demonstrated that bromoacetyl-CoA, like other short-chain CoA thioesters, is likely to interact at the malonyl-CoA site of CPT,. It is noteworthy that bromoacetyl-CoA is the first ligand reported to bind to the malonyl-CoA inhibitory site as tightly as or more tightly than malonyl-CoA itself. Third, evidence is provided that there is likely to be interaction between the site for carnitine binding and the malonyl-CoA site. These data complement those in the accompanying paper . Fourth, further inter-tissue differences are revealed regarding both the difference in the inhibitory potency of 2-bromopalmitoyl-CoA and the effect of carnitine to facilitate displacement of malonyl-CoA by both bromoacetyl-CoA and bromopalmitoyl-CoA. This work was supported by a project grant from the Medical Research Council.
